New detalimogene bladder cancer data send the minnow’s stock up 47%.
ApexOnco Front Page
Recent articles
The response rate jumps to 30% with higher doses of IMA402.
ESMO and the Triple Meeting approach.
The Kandlelit-007 trial will assess MK-1084 plus SC Keytruda across PD-L1 expression levels.
Genmab acquires the Dutch biotech for $8bn.
The ESMO presidential session will feature data from Destiny-Breast05 and 11.
Keynote-D18 features among the ESMO late-breakers, but IO Biotech can't file.
BNT329 enters the clinic, as do four other new ADCs.
